Pura Vida Investments LLC lessened its position in shares of Boston Scientific Corporation (NYSE:BSX) by 7.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 390,000 shares of the medical equipment provider’s stock after selling 30,546 shares during the quarter. Boston Scientific comprises about 5.1% of Pura Vida Investments LLC’s investment portfolio, making the stock its largest position. Pura Vida Investments LLC’s holdings in Boston Scientific were worth $11,376,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Valeo Financial Advisors LLC bought a new stake in Boston Scientific in the third quarter valued at about $138,000. Acrospire Investment Management LLC increased its holdings in Boston Scientific by 157.3% in the second quarter. Acrospire Investment Management LLC now owns 5,071 shares of the medical equipment provider’s stock valued at $141,000 after purchasing an additional 3,100 shares during the last quarter. Bronfman E.L. Rothschild L.P. increased its holdings in Boston Scientific by 14.3% in the second quarter. Bronfman E.L. Rothschild L.P. now owns 5,761 shares of the medical equipment provider’s stock valued at $160,000 after purchasing an additional 720 shares during the last quarter. San Francisco Sentry Investment Group CA bought a new stake in Boston Scientific in the second quarter valued at about $191,000. Finally, Ironwood Investment Counsel LLC bought a new stake in Boston Scientific in the third quarter valued at about $204,000. 90.57% of the stock is currently owned by institutional investors and hedge funds.

In related news, EVP Michael P. Phalen sold 15,500 shares of the stock in a transaction that occurred on Friday, September 29th. The stock was sold at an average price of $28.72, for a total transaction of $445,160.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Valley Gold Master Fund L. Sun purchased 408,006 shares of Boston Scientific stock in a transaction that occurred on Tuesday, November 28th. The shares were bought at an average cost of $0.45 per share, with a total value of $183,602.70. Insiders have sold 424,698 shares of company stock valued at $12,273,553 over the last three months. Insiders own 0.74% of the company’s stock.

Boston Scientific Corporation (NYSE:BSX) opened at $25.71 on Thursday. The company has a current ratio of 0.72, a quick ratio of 0.50 and a debt-to-equity ratio of 0.58. The stock has a market capitalization of $35,170.98, a PE ratio of 20.99, a P/E/G ratio of 1.98 and a beta of 0.96. Boston Scientific Corporation has a fifty-two week low of $21.03 and a fifty-two week high of $29.93.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Thursday, October 26th. The medical equipment provider reported $0.31 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.31. The business had revenue of $2.22 billion during the quarter, compared to the consensus estimate of $2.21 billion. Boston Scientific had a return on equity of 23.60% and a net margin of 9.55%. Boston Scientific’s quarterly revenue was up 5.6% on a year-over-year basis. During the same period last year, the company earned $0.27 earnings per share. analysts anticipate that Boston Scientific Corporation will post 1.25 EPS for the current year.

A number of research firms recently commented on BSX. BMO Capital Markets reiterated a “buy” rating and issued a $32.00 price objective on shares of Boston Scientific in a report on Tuesday. TheStreet downgraded Boston Scientific from a “b” rating to a “c+” rating in a report on Thursday, December 7th. Needham & Company LLC upgraded Boston Scientific from a “buy” rating to a “strong-buy” rating and increased their price target for the stock from $25.04 to $32.00 in a report on Friday, December 8th. SunTrust Banks set a $33.00 price target on Boston Scientific and gave the stock a “buy” rating in a report on Monday, December 4th. Finally, Cowen set a $31.00 price target on Boston Scientific and gave the stock a “buy” rating in a report on Thursday, November 30th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $31.03.

TRADEMARK VIOLATION NOTICE: This article was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US and international trademark and copyright legislation. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/12/14/pura-vida-investments-llc-sells-30546-shares-of-boston-scientific-corporation-bsx.html.

About Boston Scientific

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX).

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Stock Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related stocks with our FREE daily email newsletter.